Gaining Orphan Drug Designation at the same time is also great news. This will give CUV financial incentives to further progress their study of Scenesse in Vitiligo as well as gaining a priority review should they be successful with it.
Gaining Orphan Drug Designation at the same time is also great...
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.63 |
Change
0.120(0.89%) |
Mkt cap ! $682.3M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.77 | $13.43 | $581.2K | 42.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 248 | $13.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.64 | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |